The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

Abstract Objectives Although axitinib has achieved a preferable response rate for advanced renal cell carcinoma (RCC), patient survival remains unsatisfactory. In this study, we evaluated the efficacy and safety of a combination treatment of axitinib and a low dose of pembrolizumab‐activated autolog...

Full description

Bibliographic Details
Main Authors: Meng‐Jia Song, Qiu‐Zhong Pan, Ya Ding, Jianxiong Zeng, Pei Dong, Jing‐Jing Zhao, Yan Tang, Jingjing Li, Zhiling Zhang, Junyi He, Jieying Yang, Yue Huang, Ruiqing Peng, Qi‐Jing Wang, Jia‐Mei Gu, Jia He, Yong‐Qiang Li, Shi‐Ping Chen, Rongxing Huang, Zi‐Qi Zhou, Chaopin Yang, Yulong Han, Hao Chen, Heping Liu, Shangzhou Xia, Yang Wan, De‐Sheng Weng, Liming Xia, Fang‐Jian Zhou, Jian‐Chuan Xia
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Clinical & Translational Immunology
Subjects:
advanced renal cell carcinoma
axitinib
dendritic cells and cytokine‐induced killer cells immunotherapy
pembrolizumab
Online Access:https://doi.org/10.1002/cti2.1257

Internet

https://doi.org/10.1002/cti2.1257

Similar Items